RWE,Real World Evidence,real world evidence study,real world evidence solutions market
Real World Evidence for Medical Devices Under EU MDR — PMCF & Registry
Clinical Strategy & PMCF

Real World Evidence (RWE) for Medical Devices Under EU MDR 2017/745 — PMCF & Registry Strategy

Stop treating RWE like a pharma requirement. Discover how to leverage European registries and real-world data to secure your EU MDR compliance and power your PMCF strategy.

The EU MDR Shift: From "Nice to Have" to Mandatory PMCF

Under the Medical Device Directive (MDD), Real World Evidence (RWE) was often viewed as a supplementary marketing tool. Under EU MDR 2017/745, it has become the regulatory backbone of Post-Market Clinical Follow-up (PMCF). Notified Bodies no longer accept proactive literature searches as sufficient continuous evidence for legacy or high-risk devices.

However, generating real world evidence medical devices eu mdr requires a fundamentally different approach than pharmaceutical RWE. MedTech RWE must account for surgical learning curves, device iteration, procedural variability, and highly specific clinical outcomes. A generic pharma CRO approach will fail.

Leveraging European Registries for RWE

One of the most cost-effective and robust methods for generating real world evidence pmcf eu mdr is leveraging established European medical device registries. For orthopaedic, cardiovascular, and implantable devices, these registries provide high-quality, long-term survivorship and safety data.

A strategic rwe registry medical device approach involves aligning your PMCF endpoints with the data capture capabilities of these massive national databases, eventually aligning with the broader EUDAMED registry strategy.

NJR (UK)

The National Joint Registry is the gold standard for orthopaedic implants, providing ODEP-rating compliant data on survivorship and revision rates.

EPRD (Germany)

The Endoprothesenregister Deutschland offers massive scale for the German market, critical for demonstrating real-world safety in the EU's largest healthcare system.

Swespine (Sweden)

A highly specialized registry providing deep, longitudinal data on spinal surgery outcomes, vital for Class IIb and Class III spinal implants.

Mastering the njr eprd rwe data extraction process allows manufacturers to satisfy Notified Body requirements without the immense cost of running standalone, prospective PMCF trials from scratch.

🚀 The Eclevar Advantage: In-House Local CRAs

Accessing registry data and executing RWE studies requires deep local knowledge. As a specialized rwe medical device cro, Eclevar MedTech does not outsource monitoring. We deploy in-house Clinical Research Associates (CRAs) across the UK, Germany, France, and Sweden. This local presence ensures seamless site initiation, ethical committee (e.g., CPP in France) submissions, and high-quality real-world data capture directly from the source.

Case Study: Delivering RWE for PMCF in Wound Care

Generating RWE is not just about implants; it is equally critical for consumables and advanced therapies where clinical outcomes depend heavily on user application.

Client Success Story

RegenLab: PMCF RWE in Wound Care

The Challenge: RegenLab required robust PMCF data to support the CE marking renewal of their advanced wound care solutions under the strict requirements of EU MDR 2017/745. They needed real-world clinical data demonstrating safety and performance in standard clinical settings, without disrupting the workflow of busy wound care clinics.

The Solution: Eclevar designed and executed a targeted Real-World Evidence PMCF registry study. We utilized our MILO EDC platform to capture high-quality, structured data directly from clinical sites across Europe, focusing on wound healing trajectories and adverse event tracking.

Streamlined Capture Integrated EDC workflows minimized site burden, ensuring high physician compliance.
MDR Compliant Delivered a comprehensive PMCF Evaluation Report accepted by their Notified Body.

Extracting RWE: Beyond Registries

While national registries are powerful, they do not cover every device type. For many devices, RWE must be generated through bespoke PMCF activities. This includes:

  • Retrospective EHR Data Extraction: Mining Electronic Health Records to validate historical safety and performance claims for legacy devices.
  • High-Quality Clinical Surveys: Designing ISO 14155-compliant physician and patient surveys (PROMs) that carry actual regulatory weight, rather than acting as simple marketing questionnaires.
  • Prospective Observational Studies: Running lightweight, real-world studies using our MILO EDC platform to capture exact PMCF endpoints without the overhead of a pre-market RCT.

Choosing the right RWE strategy means balancing regulatory necessity with commercial viability. Let our team of former Notified Body reviewers help you build a PMCF plan that leverages real-world data effectively and economically.

RWE as PMCF Activity - Eclevar MedTech

RWE as a PMCF Activity

Real World Evidence collection is a powerful approach to fulfill Post-Market Clinical Follow-up (PMCF) requirements under the EU MDR while generating robust, long-term safety and performance data.

Key Objectives of RWE Data Collection

Safety Monitoring

Continuously track adverse events and safety signals in real-world patient populations over extended periods.

Performance Assessment

Evaluate device performance across diverse patient populations and clinical settings beyond pre-market trial conditions.

Long-Term Follow-up

Gather medium to long-term outcome data (months to years) to validate implant longevity and durability claims.

Regulatory Compliance

Generate evidence that meets EU MDR requirements for clinical evaluation and notified body expectations.

Comparative Analysis

Compare device outcomes with predicate devices or standard-of-care treatments in real-world settings.

Risk Mitigation

Identify and manage potential risks early through systematic data collection and analysis.

Our RWE Approach

At Eclevar MedTech, we conduct a comprehensive feasibility study before engaging in any RWE clinical study. This ensures the quality and quantity of data sources are sufficient for your intended use. We understand that the advantages of RWE are only realized with reliable, high-quality data.

Our 5-Step Methodology

1

Feasibility Assessment

Evaluate data source quality, completeness, and consistency across investigational centers.

2

Protocol Development

Design a robust RWE study protocol aligned with ISO 14155:2020, GCP, and regulatory requirements.

3

Data Collection

Systematically collect real-world data from hospital networks, registries, and clinical settings.

4

Data Analysis

Perform rigorous statistical analysis to generate clinically meaningful evidence on safety and performance.

5

Documentation & Reporting

Deliver comprehensive PMCF reports and Clinical Evaluation Reports (CER) for regulatory submission.

Data Quality Standards

Data quality encompasses completeness, consistency, and accuracy across all investigational centers. Our rigorous quality assurance processes ensure that every data point meets our high standards before analysis.

Case Study: Vascular Patch

Class III Medical Device - Real World Evidence Study

A comprehensive RWE multicentre study demonstrating how we generated robust clinical evidence for a vascular prosthesis under EU MDR requirements.

The Device

Vascular prostheses made of knitted polyester fabrics in straight tubular shapes, impregnated with ultra-purified collagen of bovine origin. Indicated for replacement or bypass of arteries damaged by aneurysm or arterial occlusive disease.

The Challenge

The Clinical Evaluation Report showed that intended claims on clinical safety and performance were not sufficiently supported by existing clinical evidence. To maintain market authorization in Europe, a comprehensive PMCF study was required to generate sufficient clinical data in compliance with EU MDR Chapter VI (sections 62-82) and ISO 14155:2020.

Study Objectives

  • Examine short and long-term outcomes of device usage
  • Evaluate performance in a larger, more varied patient population
  • Assess safety across different anatomical locations (carotid and femoral)
  • Collect data up to 3 years post-surgery

Methodology

Study Type: Multicentre RWE study with retrospective and prospective data collection from medical charts.

Patient Population: 250-300 subjects evaluated across 3-8 hospital sites.

Anatomical Coverage: Minimum 100 subjects in carotid location, minimum 100 in femoral location.

Follow-up Duration: From baseline (time of surgery) to maximum 3 years post-surgery.

Hospital Network Partners

Study Outcomes & Benefits

Robust Safety Data

Comprehensive adverse event tracking across 250-300 patients over 3 years.

Real-World Performance

Device performance validated in diverse patient populations and clinical settings.

Regulatory Approval

Evidence met EU MDR requirements and notified body expectations for CE certification.

Long-Term Validation

3-year follow-up data validated implant longevity and durability claims.

Market Confidence

Robust evidence strengthened market position and customer confidence.

Comparative Insights

Performance data across different anatomical locations (carotid vs femoral).

RWE Regulatory Framework - Eclevar MedTech

Regulatory Framework for RWE

Real World Evidence collection is governed by strict regulatory requirements across Europe. Understanding the specific requirements for your target market is essential for successful PMCF implementation and regulatory approval.

Regional Regulatory Requirements

🇪🇺

European Union

Regulation: EU MDR 2017/745

Key Requirements:

  • Chapter VI: Clinical Evidence (Articles 62-82)
  • PMCF Plan mandatory for all Class II, III, IVD devices
  • Clinical Evaluation Report (CER) required
  • ISO 14155:2020 compliance for clinical investigations
  • Notified Body review and approval
  • Competent Authority notification

Applies to all EU Member States

🇫🇷

France

Competent Authority: ANSM (National Agency for Safety of Medicines)

Key Requirements:

  • EU MDR compliance + French national requirements
  • PMCF protocols approved by ANSM
  • Ethics Committee (CPP) approval required
  • Data collection from French hospital networks
  • Annual safety reports to ANSM
  • French language documentation

Strong hospital infrastructure for RWE studies

🇩🇪

Germany

Competent Authority: BfArM (Federal Institute for Drugs)

Key Requirements:

  • EU MDR compliance + German national requirements
  • PMCF protocols submitted to BfArM
  • Ethics Committee approval mandatory
  • Data collection from German clinical centers
  • Quarterly safety reports during study
  • German language documentation

Rigorous regulatory oversight and quality standards

🇬🇧

United Kingdom

Competent Authority: MHRA (Medicines & Healthcare Products Regulatory Agency)

Key Requirements:

  • UK MDR (post-Brexit alignment with EU MDR)
  • PMCF Plan required for Class II, III devices
  • Research Ethics Committee (REC) approval
  • Data collection from UK NHS hospitals
  • Annual reports to MHRA
  • English language documentation

Well-established NHS network for clinical data

Required Documentation for RWE Studies

Comprehensive documentation is essential for regulatory approval and successful study execution. We prepare all required documentation to meet regulatory expectations across all target markets.

Documentation Categories

Protocol & Planning
Study Protocol
Detailed study design, objectives, methodology, and statistical analysis plan
PMCF Plan
Post-market clinical follow-up strategy aligned with EU MDR requirements
Feasibility Report
Assessment of data source quality and availability across centers
Risk Management Plan
Identification and mitigation of study-related risks
Ethics & Compliance
Ethics Committee Submission
Application package for CPP (France) or REC (UK) approval
Informed Consent Form (ICF)
Patient information and consent documentation in local language
Data Protection Documentation
GDPR compliance, data handling, and patient privacy safeguards
Insurance & Liability
Clinical trial insurance and liability coverage documentation
Clinical & Statistical
Statistical Analysis Plan (SAP)
Detailed methodology for data analysis and hypothesis testing
Case Report Forms (CRF)
Standardized data collection templates for all study sites
Clinical Evaluation Report (CER)
Comprehensive evaluation of clinical safety and performance data
Study Reports
Interim and final study reports with results and conclusions
Regulatory Submissions
Competent Authority Notification
Formal notification to ANSM, BfArM, or MHRA as required
Safety Reports
Periodic safety update reports (PSUR) and adverse event summaries
Notified Body Submission
Complete documentation package for technical file review
Regulatory Correspondence
Responses to regulatory questions and clarifications

Why Choose Eclevar for RWE Studies?

Hospital Network

Established relationships with leading hospitals across France, Germany, and UK

Regulatory Expertise

Deep knowledge of EU MDR, national requirements, and notified body expectations

Data Quality

Rigorous quality assurance processes ensure high-quality, compliant data collection

Efficiency

Streamlined processes reduce study timelines without compromising quality

Compliance

Full GDPR, GCP, and ISO 14155:2020 compliance across all study activities

Success Rate

Proven track record of generating evidence that meets regulatory approval standards

Ready to Generate Real World Evidence?

Let's discuss how our RWE expertise can support your medical device's regulatory strategy and market success.

Reforming Clinical Evaluation of Medical Devices in Europe